

DAFTAR PUSTAKA

- Almeida, F.A.A., Machado, F.C., Moura, J.A., dan Guimarães, A.C., 2010. Global And Cardiovascular Mortality And Risk Factors in Patients Under Hemodialysis Treatment. *Arquivos Brasileiros De Cardiologia*, **94**: 187–192, 201–206, 190–195.
- Anonim, 2004. SECTION I. Anaemia Evaluation. *Nephrology Dialysis Transplantation*, **19**: ii2–ii5.
- Anonim, 2015a. 'Iron dextran', *Drugs.com*. URL: <http://www.drugs.com/mtm/iron-dextran.html> (diakses tanggal 30/11/2015).
- Anonim, 2015b. 'Iron sucrose', *Drugs.com*. URL: <http://www.drugs.com/cdi/iron-sucrose.html> (diakses tanggal 10/12/2015).
- Arora, P., 2015. 'Chronic Kidney Disease: Practice Essentials, Background, Pathophysiology', . URL: <http://emedicine.medscape.com/article/238798-overview#a0104> (diakses tanggal 20/6/2016).
- Auerbach, M. dan Ballard, H., 2010. Clinical use of intravenous iron: administration, efficacy, and safety. *ASH Education Program Book*, **2010**: 338–347.
- Bailie, G.R., Clark, J.A., Lane, C.E., dan Lane, P.L., 2005. Hypersensitivity Reactions And Deaths Associated with Intravenous Iron Preparations. *Nephrology Dialysis Transplantation*, **20**: 1443–1449.
- Besarab, A., Amin, N., Ahsan, M., Vogel, S.E., Zazuwa, G., Frinak, S., dkk., 2000. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. *Journal of the American Society of Nephrology*, **11**: 530–538.
- Brunner, L. dan D, S., 2002. *Buku Ajar Keperawatan Medikal Bedah*, 1st ed. EGC, Jakarta.
- Cavill, I., 2002. Iron and erythropoietin in renal disease. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, **17 Suppl 5**: 19–23.
- Cavill, I., 2003. Intravenous iron as adjuvant therapy: A two-edged sword? *Nephrol Dial Transplant* **18**: viii24–viii28.

- Cibulka, R. dan Racek, J., 2007. Metabolic disorders in patients with chronic kidney failure. *Physiological Research / Academia Scientiarum Bohemoslovaca*, **56**: 697–705.
- Comstock, T.J., 2009. Renal Dialysis, dalam: *Applied Therapeutics: The Clinical Use of Drugs*. Wolters Kluwer/Lippincott Williams & Wilkins, USA.
- DEPKESRI, 2013. 'Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/MENKES/SK/VIII/2013', . Departemen Kesehatan Republik Indonesia, Jakarta.
- Dipiro, J.T., Fccp, D.J.T.D. Pharm D., Schwinghammer, T.L., Talbert, R.L., Yee, G.C., Matzke, G.R., dkk., 2005. Hemodialysis and Peritoneal Dialysis, dalam: *Dipiro J.T. (Ed.) Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill, New York.
- Drüeke, T., 2001. Hyporesponsiveness to recombinant human erythropoietin. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, **16 Suppl 7**: 25–28.
- Hall, J.E. dan Guyton, A.C., 2007. *Guyton dan Hall buku ajar fisiologi kedokteran*, hal. 529-578.
- Hörl, W.H., 2013. Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease. *Drugs*, **73**: 117–130.
- Horl, W.H., 2007. Clinical Aspects of Iron Use in the Anemia of Kidney Disease. *Journal of the American Society of Nephrology*, **18**: 382–393.
- Hudson, J.Q., 2008. Chronic Kidney Disease: Therapeutic Approach for Management of Complications, dalam: *Dipiro J.T. (Ed.) Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Professional, USA, hal. 765–792.
- Ineck, B.A., Mason, B.J., dan Lyons, L., 2008. Anemia, dalam: *Dipiro J.T. (Ed.) Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Professional, USA, hal. 1639–1664.
- Joy, M.S., A, K., dan N., F., 2008. Chronic Kidney Disease: Progression-Modifying Therapies, dalam: *Dipiro J.T. (Ed.) Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Professional, hal. 745–764.
- KDIGO, 2013. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*, **2**: 1.

- Kee, J.L., 1997. *Buku Saku Pemeriksaan Laboratorium Dan Diagnostik Dengan Implikasi Keperawatan*. Penerbit Buku Kedokteran EGC, Jakarta.
- Lankhorst, C.E. dan Wish, J.B., 2010. Anemia in renal disease: diagnosis and management. *Blood Reviews*, **24**: 39–47.
- Lippincott, W.& W., 2012. *Koda-Kimble & Young's Applied Therapeutics, The Clinical Use of Drugs*, 10th ed. Lippincott Williams & Wilkins.
- Litton, E., Xiao, J., dan Ho, K.M., 2013. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. *BMJ*, **347**: f4822–f4822.
- Longo, D., Fauci, A., Kasper, D., Hauser, S., dan Jameson, J., 2012. *Harrisons Manual of Medicine*, 18th ed. McGraw Hill Professional.
- Macdougall, I.C., 1999. Strategies for iron supplementation: Oral versus intravenous. *Kidney International*, **55**: S61–S66.
- Marriot, J. dan S., (Smith), 2003. Chronic Renal Failure, In Walker, Roger, dan Edward, Clive, (Eds), dalam: *Clinical Pharmacy and Therapeutic*. McGraw-Hill, San Francisco, hal. 247–264.
- NKF-K/DOQI, 2006. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **47**: S11–145.
- NKF-K/DOQI, 2010. Clinical Practice Guidelines for Chronic Kidney Disease : How Your Kidney's Work? *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **47**: S11–145.
- O'Bryant, C.L. dan Utz, K.J., 2012. Anemias, dalam: *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins, USA.
- O'Hare, A.M., Choi, A.I., Bertenthal, D., Bacchetti, P., et al., 2007, Age Affects Outcomes in Chronic Kidney Disease, *J. Am. Soc. Nephrol.*, **18** (10): 2758-2765.
- Perazella, M.A., 2005. Chronic Kidney Disease, dalam: *Reilly, R.F, Jr., Perazella, M.A. (Ed.) Nephrology in 30 Days*. McGraw-Hill Education, hal. 251–274.
- PERNEFRI, 2011. *Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik*, 2nd ed. PERNEFRI, Jakarta.

- Pollock, P.S., Swinkels, D.W., Wanner, C., Weiss, G., dan Glenn, M., 2014. Iron Management in Chronic Kidney Disease: Report from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
- Prince, S. dan Wilson, L., 2005. *Patofisiologi: Konsep Klinis Proses-Proses Penyakit*, 6th ed. EGC, Jakarta.
- Schonder, K.S., 2008. Chronic & End Stage Renal Disease, dalam: *Dipiro J.T. (Ed.) Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Companies Inc.
- Sidabutar, R.P., Suhardjono, dan Kapojos, J., n.d. Gagal Ginjal Kronik, dalam: *Ilmu Penyakit Dalam*. FKUI, Jakarta, hal. 344–362.
- Suctonia, C.P., Valeria, S., Dimitris, M., Georgia, S., 2014. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. *Cochrane Database Syst. Rev.* doi:10.1002/14651858.CD010590.pub2
- Suwitra, K., 2009. Penyakit Ginjal Kronik, dalam: *Buku Ajar Ilmu Penyakit Dalam*. hal. 1035–40.
- Taler, S.J., Agarwal, R., Bakris, G.L., Flynn, J.T., Nilsson, P.M., Rahman, M., dkk., 2013. KDOQI US Commentary on The 2012 KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *American journal of kidney diseases*, **62**: 201–213.
- Tierney, L.M., 1993. *Current Medical Diagnosis and Treatment*. Appleton & Lange.
- Vanasse, G.J. dan Berliner, N., 2010. Anemia in Elderly Patients: an Emerging Problem for The 21st Century. *ASH Education Program Book*, **2010**: 271–275.
- Walters, B.A.J. dan Van Wyck, D.B., 2005. Benchmarking Iron Dextran Sensitivity: Reactions Requiring Resuscitative Medication in Incident and Prevalent Patients. *Nephrology Dialysis Transplantation*, **20**: 1438–1442.
- WHO, 2007. Assessing The Iron Status of Populations. 2 1–221.